Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study. These data were publi ...

These data were presented in two oral presentations at the American Heart Association ... Forty-four patients had genetically confirmed FCS and 31 patients had clinically diagnosed FCS. Plozasiran, at ...

Arrowhead Pharmaceuticals, Inc. today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These ...

Natural Grocers Kicks Off Holiday Events. Natural Grocers is celebrating the holiday season with its annual in-store holiday food bank fundraiser and food drive. The campaign, whi ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...

We also only tend to genetically test folks who are symptomatic already ... some non-specialist clinicians may have a hard ...

Award presentations will be made at the WPAG Holiday Potluck Luncheon ... The day includes lectures and demonstrations; check ...

Portfolio management, financial planning, trustee, responsible entity and compliance services, executor services, investment administration and custody services.